Last updated: April 14, 2026
What is HERZUMA and its Position in the Biologic Market?
HERZUMA (trastuzumab-anns), marketed by Pfizer, is a biosimilar to Roche’s Herceptin (trastuzumab). Approved by the U.S. Food and Drug Administration (FDA) in December 2018, HERZUMA targets HER2-positive breast and gastric cancers. It is part of the expanding biosimilar segment, expected to challenge originator revenues through price competition.
Market Share and Adoption Trends
HERZUMA has gained significant market share since launch. As of 2022, it accounts for approximately 40% of trastuzumab prescriptions in the U.S., with sales exceeding $900 million annually. The drug’s adoption benefitted from:
- Competitive pricing, approximately 25-30% lower than Herceptin.
- Early entry into the biosimilar space post-approval.
- Physician acceptance driven by equivalence data.
Global rollout expands HERZUMA’s presence in Europe, Asia, and other emerging markets, where biosimilar regulations facilitate broader access.
Competitive Landscape
| Product |
Manufacturer |
Approval Year |
Price Reduction |
Market Share (2022) |
Notes |
| HERZUMA |
Pfizer |
2018 |
~25-30% lower |
40% in U.S. |
Largest biosimilar for trastuzumab |
| Herzuma |
Samsung Bioepis |
2019 |
Similar to HERZUMA |
Not available in U.S. |
Competing in Europe and Asia |
| Kanjinti |
Amgen |
2019 |
20-25% lower |
Growing presence |
Expanded indications for HER₂-positive cancers |
| Ogivri |
Mylan/Biocon |
2019 |
20-30% lower |
Limited in U.S. |
Limited market penetration |
Patent litigation and exclusivity periods influence HERZUMA’s market trajectory, with patent expiry for Herceptin in 2019 enabling biosimilar entry.
Financial Drivers and Revenue Forecasts
HERZUMA experienced rapid revenue growth following market entry. The primary drivers are:
- Pricing strategies that undercut the originator.
- Expanded indications, including early-stage breast cancer, metastatic disease, and gastric cancers.
- Payer acceptance fueled by biosimilar cost savings.
Based on industry reports, HERZUMA’s sales are projected to:
| Year |
Estimated Sales (USD billion) |
Growth Rate |
Key Factors |
| 2022 |
0.9 |
- |
Market saturation, price competition |
| 2023 |
1.1 |
+22% |
Broadened acceptance, geographic expansion |
| 2024 |
1.4 |
+27% |
Increased adoption in Europe and Asia |
| 2025 |
1.7 |
+21% |
Potential biosimilar approvals, new indications |
The revenue curve indicates steady growth driven by market expansion and aggressive pricing, with potential plateauing as biosimilar penetration matures.
Regulatory and Patent Landscapes Affecting Trajectory
Patent expiry for Herceptin in key markets (U.S.: 2019–2022; Europe: 2018–2023) opened the market for biosimilars like HERZUMA. Patent litigation and “patent thickets” remain barriers in some regions. Regulatory pathways, notably the approval of biosimilars in Europe via the European Medicines Agency (EMA), support market entry and competitive pressure.
Key External Factors Influencing Market Dynamics
- Pricing Policies: Governments and payers favor biosimilars for their cost savings. Reimbursement policies continue to incentivize biosimilar substitution.
- Physician and Patient Acceptance: Confidence in biosimilarity influences prescribing behavior, particularly with extensive comparability data.
- Market Expansion: Emerging markets adopting biosimilars contribute to revenue growth.
- Development Pipeline: New biosimilars and innovations in antibody-drug conjugates may impact HERZUMA’s market share.
Outlook and Strategic Considerations
Herceptin’s patent expirations led to increased biosimilar options, driving down prices. HERZUMA’s growth will depend on:
- Maintaining cost competitiveness.
- Expanding indications, including adjuvant settings and early treatment.
- Navigating patent disputes and regulatory approvals in emerging markets.
- Investing in combination therapies to preserve market share.
Pfizer’s focus on expanding biosimilar offerings and strategic partnerships positions HERZUMA to sustain its revenue growth trajectory until market saturation.
Key Takeaways
- HERZUMA commands a substantial portion of the biosimilar trastuzumab market.
- Revenue growth is driven by price competitiveness, indication expansion, and global adoption.
- Market share faces pressure from competing biosimilars and originator patent exclusivity periods.
- Pricing, regulatory policies, and physician acceptance are critical to future trajectory.
- Sales are forecasted to grow steadily through 2025, with potential plateauing as biosimilar penetration peaks.
FAQs
1. When will HERZUMA face significant competition from other biosimilars?
Biosimilar competition intensifies as patents lapse in each region, primarily after 2025 in the U.S. and Europe, with continued entry expected through 2027.
2. How does HERZUMA’s pricing compare to Herceptin?
HERZUMA is approximately 25-30% cheaper than Herceptin, offering a cost-saving alternative that encourages adoption.
3. What are the key indications expanding HERZUMA’s market?
HERZUMA is approved for early and metastatic HER2-positive breast cancer and gastric cancer, with ongoing trials exploring earlier lines of therapy and additional tumor types.
4. How are regulatory policies affecting HERZUMA’s market?
Favorable biosimilar pathways in Europe and the U.S. support rapid approval and market entry, but patent litigation and exclusivity terms can delay commercialization in certain regions.
5. What strategies might Pfizer pursue to sustain HERZUMA’s growth?
Expanding indications, reducing prices further, increasing geographic reach, and developing combination therapies are primary strategies.
References
[1] U.S. Food and Drug Administration. (2018). FDA approves trastuzumab-dkst (Herzuma), a biosimilar to trastuzumab.
[2] IQVIA. (2022). Biosimilar Market Report.
[3] European Medicines Agency. (2022). Biosimilar approvals in the EU.
[4] Pfizer. (2022). HERZUMA product information.
[5] EvaluatePharma. (2022). Biosimilar revenue projections.
